Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.10(n)  

 
 

LEASE AMENDMENT "9"    
    

        THIS AMENDMENT is attached to and hereby forms a part of that certain LEASE ("Lease") made the 1 st day of December, 1994, by and between Green, Praver Et AI
("Landlord") and Anesta Corp., a Delaware Corporation. WHEREAS, Tenant and Landlord desire to memorialize their understanding and to amend the Lease consistent therewith. NOW, THEREFORE, in
consideration of the mutual covenants and conditions contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Tenant and Landlord agree
as follows: 

1.    LEASE TERM EXTENSION

        Tenant
hereby exercises its first of two three (3) year option periods to extend its Lease for Suite 540 of Wiley Post Plaza consisting of 7,134 square feet. The Extended Term
will commence July 1, 2003 and will end June 30, 2006. 

2.    RENTAL RATES

        For
this Expansion Term for Suite #540, Tenant agrees to pay to Landlord, without prior notice or demand, as annual base rental the sum of [**] for the first year
of the Extended Term, payable in equal monthly payments of [**] on or before the first days of each month in advance. The first month's rent for the Extended Term shall be paid
on or before July 1, 2003. The annual base rent for Suite #540 shall be increased each year, effective on each anniversary of the date by a percentage equal to the percentage increase in the
United States Department of Labor Statistics New Consumer Price Index for all Urban Consumers (CPI-U, National Index, 1982-1984 = 100) as published by the United States
Department of Labor, Bureau of Labor Statistics, using as a base the index for the two months immediately preceding the commencement of the Extended Term compared to the index for the two months
immediately preceding the anniversary date of the year for which the lease adjustment is being made. The foregoing notwithstanding, the annual base rent shall not be increased by more than three
percent in any one year. 

3.    ADDITIONAL RENT—EXPANSION PREMISES

        Tenant
shall continue to pay, as additional rent for Suite #540, Tenant's proportionate share of "Basic Costs Increases" as defined in Section 2.3 of the Lease.
"Tenant's Proportionate Share" for Suite #540 shall mean 3.74 percent, which is determined by dividing the 7,134 square feet being rented by
Tenant by 190,628 square feet, the total rentable space in the Project. The monthly charge for additional rent for the expansion space is [**] which represents the 7,134 square
feet times [**]. The additional rent rate of [**] shall be adjusted annually or at such time as there is a significant change in the costs of any item
of additional rent to be paid by 

**    Portions
of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to
Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

 

Tenant
as per Section 2.3. of the Lease. 

4.    VALID AGREEMENTS

        Tenant
and Landlord acknowledge that the Lease (with Amendments 1 through 8) is a valid and enforceable agreement and that the Tenant holds no claims against Landlord or its
agents which might serve as the basis of any set-off against accruing rent and other charges or any other remedy in law or in equity. Except as is herein specifically modified and amended
or as is necessary to give meaning and effectuate the terms hereof, the Lease shall remain in full force and effect, it being understood and agreed that this Amendment, upon execution, becomes a part
of the total Lease. 

5.    BROKERS

        Except
as herein set out, Tenant represents, and warrants that there are no claims for brokerage commissions or finder's fees in connection with this Lease and agrees to indemnify
Landlord against and hold it harmless from all liabilities arising from such claim, including any attorney's fees connected therewith. Landlord shall pay the brokerage fees and/or commissions payable
in connection with this Lease to Asset Management Services, Inc., who represents Landlord, pursuant to the applicable listing and/or brokerage agreement between Landlord and said party. 

6.    AUTHORITY OF SIGNATORIES

        The
persons executing this Lease Amendment "9" on behalf of Landlord and Tenant, each represent and warrant that he or she has the authority to execute this Agreement and to bind the
respective party. By signing this document on behalf of Landlord, the Property Manager (Gregory W. Strong) executing this Amendment on Landlord's behalf
does not, by signing this Amendment in that capacity, agree to assume any personal liability or to perform any of the obligations under this Amendment. Such Property Manager is, however, authorized to
execute this Amendment on Landlord's behalf and has the authority to bind Landlord to perform the terms of this Amendment. 

IN
WITNES WHEREOF, the parties have duly executed this Amendment this 15th day of May, 2003. 

	

LANDLORD: GREEN PRAVER ET AL	
 	

TENANT: ANESTA CORP.
	 	 	 	 	 	 	 
	By:	 	/s/  GREGORY W. STRONG      
 Gregory W. Strong

Project Manager	 	By:	 	/s/  ROGER P. EVANS      
 Robert J. Urban

Vice President, Technical Operations

2

 
EXHIBIT A  

 
 

DESCRIPTION OF PREMISES    
    

  

3

QuickLinks

LEASE AMENDMENT "9"

DESCRIPTION OF PREMISESEXHIBIT 10.11(e)  

April 28,
2003 

Ms. Trudy
Briley

DSM Pharmaceuticals, Inc.

P.O. Box 1887

Greenville, NC 27835-1887 

	Re:
	Amendment
No. 4 to Toll Manufacturing and Packaging Agreement 

Dear
Ms. Briley: 

        This
letter is to confirm our understanding concerning an amendment to be made with respect to the Toll Manufacturing and Packaging Agreement dated as of August 24, 1999, as
amended by Amendment No.1 dated July 3, 2001, by Amendment No. 2 dated October 9, 2001, and by Amendment No. 3 dated June 21, 2002 (the "Agreement"), between
Cephalon, Inc. ("Cephalon") and DSM Pharmaceuticals, Inc. ("DSM"). All terms not otherwise defined herein are used as defined in the Agreement. 

        The
purpose of this Amendment is to extend the Initial Term of the Agreement for one year and to set the minimum annual quantities of Product to be purchased by Cephalon and to increase
the manufacturing capacity reserved by Catalytica for the remainder of the Initial Term of the Agreement. The Agreement is hereby amended as follows: 

        1.
In the second line of Section 2.5 of the Agreement, the words "five (5)" are hereby replaced with words "six (6)." 

        2.
Existing Schedule F of the Agreement relating to Minimum Quantities shall be deleted in its entirety and replaced with the attached revised Schedule F. 

        3.
Except as amended hereby, the Agreement remains in full force and effect. 

        If
the foregoing accurately reflects your understanding as to these matters, please indicate your agreement in the space provided below, and return one fully-executed original to me. 

	 	 	 	Very truly yours,
	

 	

 	
 	

/s/ Robert Urban

Vice President, Technical Operations
	

Acknowledged and agreed to by:	
 	

 
	

DSM PHARMACEUTICALS, INC.	
 	

 
	

By:	

/s/  TERENCE S. NOVAK      
 Name: Terence S. Novak

Title: Sr. V.P. Comm. Ops.	
 	

 

 
Schedule F

Minimum Quantities  

        The minimum annual quantities to be purchased by CEPHALON and capacity to be reserved by DSM, are as follows for the remainder of the Initial Term of this
Agreement: 

	Year
 
	 	Quantity

	2004	 	[**]
	2005 (until 8/24/05)	 	[**]

        Pursuant
to Section 3.1, if the actual annual quantity exceeds the minimum annual quantity in any year by twenty-five percent (25%) or less, this excess will reduce
the minimum annual quantity in the following year. 

	**
	Portions
of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule
24b-2 under the Securities Exchange Act of 1934, as amended. 

A-1EXHIBIT 10.11(f)  

August 15,
2003 

Mr. Robert
Urban

Vice President, Technical Operations

Cephalon, Inc.

145 Brandywine Parkway

West Chester, PA 19380 

	Re:
	Amendment
No. 5 to Toll Manufacturing and Packaging Agreement 

        This
letter is to confirm our agreement to amend the Toll Manufacturing and Packaging Agreement dated as of August 24, 1999, as amended by Amendment No.1 dated July 3,
2001, by Amendment No. 2 dated October 9, 2001, by Amendment No. 3 dated June 21, 2002, and by Amendment No. 4 dated April 28, 2003 (collectively, the
"Agreement"), between Cephalon, Inc. ("Cephalon") and DSM Pharmaceuticals, Inc. ("DSM"). All terms not otherwise defined herein are used as defined in the Agreement. 

        The
purpose of this Amendment No. 5 is to update the Tolling Fees for Product listed in existing Schedule E to include Provigil Aqueous Formulation Tablets. The Agreement
is hereby amended as follows: 

Existing
Schedule E of the Agreement relating to Tolling Fees shall be deleted in its entirety and replaced with the attached revised Schedule E. 

        If
you agree with Amendment No. 5 as stated herein, please sign both copies of this amendment in the space below and return one signed original to me. 

Sincerely,

	 
	 
	 	 

	

/s/  TERENCE S. NOVAK      
 Terence S. Novak

Senior Vice President Commercial Operations	
 	

 
	

Amendment No. 5 accepted and agreed:	
 	

 
	

CEPHALON, INC.	
 	

 
	

By:	

/s/  ROBERT J. URBAN      
	
 	

 
	

Name: Robert J. Urban

Title: Vice President, Manufacturing & Engineering

 
Schedule E

Tolling Fees  

        Cephalon shall pay DSM the following amounts in consideration of the formulations and packaging services rendered hereunder: 

	 
	 	Current Formulation

(Compressil Formula)
	 	New Formulation

(Aqueous Formula)

	Provigil 100mg, bulk tablets	 	[**]	 	[**]
	Provigil 100mg, 100 count bottles	 	[**]	 	[**]

	 
	 	Current Formulation

(Compressil Formula)
	 	New Formulation

(Aqueous Formula)

	Provigil 200mg, bulk tablets	 	[**]	 	[**]
	Provigil 200mg, 100 count bottles	 	[**]	 	[**]

        The
above prices do not include the cost of Modafinil or Magnerium Silicate (Compressil), but do include packaging material costs. These prices are based on batches being campaigned once
per quarter. 

        Annual
price increases will be invoked as per Section IV of the Toll Manufacturing and Packaging Agreement (dated August 24, 1999) (the "Agreement"). The review of the
annual pricing is based on the Producer Price Index (PPI) for the prior year Pharmaceutical Preparations, series code
PCU-2834# as published by the Bureau of Labor Statistics of the U.S. Department of Labor. 

	**
	Portions
of this exhibit have been omitted and filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule
24b-2 under the Securities Exchange Act of 1934, as amended. 

A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]